Department of Pharmaceutical Sciences, The University of Tennessee Health Science Center (UTHSC), 881 Madison Avenue, Memphis, TN 38103, USA.
Department of Cell and Developmental Biology, University of South Carolina, Columbia, SC 29208, USA.
Cells. 2021 Apr 24;10(5):1004. doi: 10.3390/cells10051004.
Obesity is characterized as a complex and multifactorial excess accretion of adipose tissue (AT) accompanied with alterations in the immune response that affects virtually all age and socioeconomic groups around the globe. The abnormal accumulation of AT leads to several metabolic diseases, including nonalcoholic fatty liver disorder (NAFLD), low-grade inflammation, type 2 diabetes mellitus (T2DM), cardiovascular disorders (CVDs), and cancer. AT is an endocrine organ composed of adipocytes and immune cells, including B-Cells, T-cells and macrophages. These immune cells secrete various cytokines and chemokines and crosstalk with adipokines to maintain metabolic homeostasis and low-grade chronic inflammation. A novel form of adipokines, microRNA (miRs), is expressed in many developing peripheral tissues, including ATs, T-cells, and macrophages, and modulates the immune response. miRs are essential for insulin resistance, maintaining the tumor microenvironment, and obesity-associated inflammation (OAI). The abnormal regulation of AT, T-cells, and macrophage miRs may change the function of different organs including the pancreas, heart, liver, and skeletal muscle. Since obesity and inflammation are closely associated, the dysregulated expression of miRs in inflammatory adipocytes, T-cells, and macrophages suggest the importance of miRs in OAI. Therefore, in this review article, we have elaborated the role of miRs as epigenetic regulators affecting adipocyte differentiation, immune response, AT browning, adipogenesis, lipid metabolism, insulin resistance (IR), glucose homeostasis, obesity, and metabolic disorders. Further, we will discuss a set of altered miRs as novel biomarkers for metabolic disease progression and therapeutic targets for obesity.
肥胖症的特征是脂肪组织(AT)的复杂和多因素过度积累,伴随着免疫反应的改变,几乎影响到全球所有年龄和社会经济群体。AT 的异常积累导致多种代谢疾病,包括非酒精性脂肪性肝病(NAFLD)、低度炎症、2 型糖尿病(T2DM)、心血管疾病(CVDs)和癌症。AT 是由脂肪细胞和免疫细胞组成的内分泌器官,包括 B 细胞、T 细胞和巨噬细胞。这些免疫细胞分泌各种细胞因子和趋化因子,并与脂肪因子相互作用,以维持代谢平衡和低度慢性炎症。一种新型的脂肪因子,microRNA(miRs),在许多发育中的外周组织中表达,包括 ATs、T 细胞和巨噬细胞,并调节免疫反应。miRs 对于胰岛素抵抗、维持肿瘤微环境和肥胖相关炎症(OAI)至关重要。AT、T 细胞和巨噬细胞中 miRs 的异常调节可能改变包括胰腺、心脏、肝脏和骨骼肌在内的不同器官的功能。由于肥胖和炎症密切相关,炎症脂肪细胞、T 细胞和巨噬细胞中 miRs 的失调表达表明 miRs 在 OAI 中的重要性。因此,在这篇综述文章中,我们阐述了 miRs 作为表观遗传调节剂在影响脂肪细胞分化、免疫反应、AT 褐变、脂肪生成、脂质代谢、胰岛素抵抗(IR)、葡萄糖稳态、肥胖和代谢紊乱中的作用。此外,我们将讨论一组改变的 miRs 作为代谢疾病进展的新型生物标志物和肥胖的治疗靶点。